Code
BT-MCA2695
Host
Mouse
Isotype
Mouse IgG2b
Size
100μL,50μL
Clonality
Monoclonal
Immunogen
Purified recombinant fragment of human MAPK expressed in E. Coli.
Formulation
Ascitic fluid containing 0.03% sodium azide.
Storage
Store at 4°C short term. Aliquot and store at -20°C long term.
Background
Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines and is an important target in the diagnosis and treatment of cancer. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK and the transcription factor Elk-1. p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs, along with MEK inhibitors such as U0126 and PD98059.
Uniprot accession
Molecular weight
42kDa
Gene ID
5594
Synonyms
ERK;p38;p40;p41;ERK2;ERT1;MAPK2;PRKM1;PRKM2;P42MAPK;p41mapk;MAPK1
Research area
Others
Target protein
p44/42 MAPK (Erk1/2)
